Dronedarone Hydrochloride and Wakix

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.CONTRAINDICATED: Dronedarone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In healthy subjects given repeated oral doses, dronedarone induced a QTc prolongation of about 10 ms at 400 mg twice daily and up to 25 ms at 1600 mg twice daily. In clinical trials using a dosage of 400 mg twice daily, premature discontinuation of therapy due to QT prolongation occurred in 1.5% of dronedarone patients versus 0.5% of placebo patients. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). MANAGEMENT: Coadministration of dronedarone with other drugs that can prolong the QT interval is considered contraindicated. References Cerner Multum, Inc. "Australian Product Information." O 0 Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Multaq (dronedarone)." sanofi-aventis , Bridgewater, NJ. Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink." View all 4 references

CONTRAINDICATED: Dronedarone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In healthy subjects given repeated oral doses, dronedarone induced a QTc prolongation of about 10 ms at 400 mg twice daily and up to 25 ms at 1600 mg twice daily. In clinical trials using a dosage of 400 mg twice daily, premature discontinuation of therapy due to QT prolongation occurred in 1.5% of dronedarone patients versus 0.5% of placebo patients. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).

MANAGEMENT: Coadministration of dronedarone with other drugs that can prolong the QT interval is considered contraindicated.

Dronedarone Hydrochloride

Generic Name: dronedarone

Brand name: Multaq

Synonyms: Dronedarone

What is Dronedarone Hydrochloride?

Wakix

Generic Name: pitolisant

Brand name: Wakix

Synonyms: Wakix Tablets

What is Wakix?